Foundayo™ (orforglipron), Lilly's new oral GLP-1 pill for weight loss, now available in the U.S.

Rhea-AI Summary

Eli Lilly (NYSE: LLY) announced Foundayo (orforglipron) is now available in the U.S. after FDA approval on April 1, 2026, with retail pharmacy shipping beginning April 9, 2026.

Foundayo is a once-daily oral GLP-1 for adults with obesity or overweight with weight-related problems, showing an average weight loss of 27.3 pounds (12.4%) at the highest dose in ATTAIN-1.

Positive

• FDA approval effective April 1, 2026
• U.S. availability began April 9, 2026
• Average weight loss 27.3 lb (12.4%) at highest dose
• Commercially insured cost as low as $25/month

Negative

• Self-pay starting price of $149/month
• Not recommended with other GLP-1 medicines
• Safety warning: potential thyroid tumors including cancer

News Market Reaction – LLY

+0.20%

+0.20% Session close to close

In the Apr 9 session, LLY gained 0.20%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement marks the U.S. commercial availability of Foundayo, Lilly’s once-daily oral GLP-1 ...

Analysis

This announcement marks the U.S. commercial availability of Foundayo, Lilly’s once-daily oral GLP-1 pill for weight loss, following FDA approval on April 1, 2026. Supported by ATTAIN trial data showing average losses up to 27.3 pounds (12.4%), the drug is offered at structured prices from $25 to $149 per month depending on coverage. Key considerations include the boxed thyroid tumor warning, common gastrointestinal side effects, and variability in obesity drug insurance coverage, which will influence real-world adoption and persistence.

Key Figures

Commercial copay: $25 per month Self-pay price: $149 per month Medicare cost: $50 per month +5 more

8 metrics

Commercial copay $25 per month Eligible commercially insured patients with Foundayo coverage

Self-pay price $149 per month Self-pay patients, lowest dose Foundayo

Medicare cost $50 per month Eligible Medicare Part D individuals from Jul 1, 2026

Average weight loss 27 pounds Highest dose Foundayo in ATTAIN-1, on treatment

Weight loss percent 12.4% Highest dose Foundayo in ATTAIN-1, on treatment

Placebo weight loss 2.2 pounds (0.9%) Placebo group in ATTAIN-1, on treatment

All-patient weight loss 25 pounds (11.1%) All Foundayo participants regardless of completion

All-patient placebo loss 5.3 pounds (2.1%) All placebo participants regardless of completion

Historical Context

5 past events · Latest: Apr 01 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Apr 01	Foundayo FDA approval	Positive	+3.8%	FDA approval of Foundayo oral GLP-1 for obesity and overweight adults.
Mar 31	Centessa acquisition	Positive	+3.7%	Agreement to acquire Centessa to expand neuroscience and sleep disorder pipeline.
Mar 27	EBGLYSS long-term data	Positive	-2.1%	Four-year durability data for EBGLYSS in moderate-to-severe atopic dermatitis.
Mar 19	Retatrutide Phase 3	Positive	-0.1%	Positive Phase 3 topline data for retatrutide in type 2 diabetes with weight loss.
Mar 16	EBGLYSS pediatric trial	Positive	-0.2%	Phase 3 outcomes for EBGLYSS in pediatric atopic dermatitis patients.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent obesity/weight-loss and strategic news (Foundayo FDA approval, Centessa acquisition) have been followed by positive one-day moves, while some dermatology and other clinical updates saw modest negative or flat reactions.

Recent Company History

Over the past month, Lilly has reported several major milestones. On Mar 16 and Mar 27, positive Phase 3 data for EBGLYSS in atopic dermatitis and long-term durability produced small negative moves. On Mar 19, strong Phase 3 data for retatrutide in type 2 diabetes saw a flat reaction. Strategic expansion via the Centessa acquisition on Mar 31 and FDA approval of oral GLP-1 pill Foundayo on Apr 1 both coincided with solid gains, framing today’s commercial availability news as a continuation of the obesity franchise rollout.

Key Terms

glp-1, u.s. food and drug administration (fda), placebo, non-hdl cholesterol, +4 more

8 terms

glp-1 medical

"Foundayo, the only GLP-1 pill for weight loss that can be taken any time..."

GLP-1 (glucagon-like peptide-1) is a natural hormone in the body that helps regulate blood sugar levels and appetite. Its significance to investors lies in its role as the basis for a class of medications that address conditions like type 2 diabetes and obesity, which are large and growing markets. Advances or investments in GLP-1-based treatments can signal opportunities in healthcare innovation and potentially impact pharmaceutical companies’ growth.

u.s. food and drug administration (fda) regulatory

"following the U.S. Food and Drug Administration (FDA) approval on April 1, 2026."

The U.S. Food and Drug Administration (FDA) is a government agency responsible for protecting public health by ensuring the safety and effectiveness of food, medicines, vaccines, and other health-related products. For investors, the FDA’s decisions can significantly impact companies in the healthcare and food industries, as approval or rejection of products can influence a company's success and stock performance.

placebo medical

"27.3 pounds (12.4%) compared to 2.2 pounds (0.9%) with placebo."

A placebo is an inactive pill, injection or procedure that looks and feels like the real treatment but contains no therapeutic ingredient, often called a sugar pill. Investors care because comparing a drug to a placebo reveals whether observed benefits come from the medicine itself or from expectation; clear superiority over placebo reduces regulatory and commercial risk, much like a blind taste test proves a new recipe really tastes better.

non-hdl cholesterol medical

"reductions in many markers of cardiovascular risk, including waist circumference, non-HDL cholesterol..."

Non-HDL cholesterol is the total amount of blood cholesterol carried by all particles that can clog arteries, calculated by subtracting 'good' HDL cholesterol from total cholesterol; think of it as counting all the cars that can cause traffic jams rather than just one type. It matters to investors because higher non-HDL levels predict greater risk of heart disease across populations, which can influence healthcare costs, workforce productivity, insurance liabilities, and demand for drugs or medical services.

triglycerides medical

"including waist circumference, non-HDL cholesterol, triglycerides and systolic blood pressure..."

Triglycerides are the main form of fat carried in the bloodstream, made from excess calories and used by the body for energy or stored in fat tissue; think of them as the oil reserves that fuel the body. They matter to investors because high or low levels influence demand for drugs, diagnostics, and healthcare services, affect regulatory reviews and insurance costs, and signal population health trends that can change market size and company risk.

systolic blood pressure medical

"non-HDL cholesterol, triglycerides and systolic blood pressure across all doses."

Systolic blood pressure is the top number in a blood pressure reading, measuring the pressure in your arteries when your heart beats and pumps blood. It indicates how forcefully the heart pushes blood through the body. For investors, it can symbolize the maximum stress or intensity in a system, helping to assess overall health risks or stability.

telehealth technical

"People can now access Foundayo via LillyDirect® and telehealth providers..."

Telehealth is the delivery of healthcare services and consultations remotely using video calls, phone, text messaging, or connected devices to monitor and transmit medical information. It matters to investors because it can reshape how patients access care, lower costs, and create new revenue streams or risks for healthcare providers, insurers and technology companies—similar to how online banking changed financial services—while also exposing businesses to reimbursement and regulatory shifts.

glp-1 receptor agonist medical

"Use of Foundayo with other GLP-1 receptor agonist medicines is not recommended."

A GLP-1 receptor agonist is a medicine that mimics a natural gut hormone to trigger insulin release, slow stomach emptying, and curb appetite — like using a key to turn on a lock that controls blood sugar and hunger signals. For investors, these drugs matter because they treat common conditions such as diabetes and obesity, can drive large prescription and sales growth, reshape healthcare costs, and heavily affect drug pipelines, competition and company valuations.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Foundayo is now available via LillyDirect^® and telehealth providers and is shipping to retail pharmacies nationwide

Foundayo, the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions, starts at $25 per month with commercial coverage and $149 per month with self-pay

INDIANAPOLIS, April 9, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that Foundayo™ (orforglipron) is now available to adults with obesity or overweight with weight-related medical problems following the U.S. Food and Drug Administration (FDA) approval on April 1, 2026. When used alongside a reduced-calorie diet and increased physical activity, Foundayo helps individuals lose excess body weight and keep the weight off. Foundayo is a once-daily pill for weight loss that can be taken without food or water restrictions. People can now access Foundayo via LillyDirect^® and telehealth providers, with availability expanding to U.S. retail pharmacies beginning today.

"Foundayo delivers meaningful weight loss – an average of 27 pounds at the highest dose – and we made the path from prescription to doorstep as simple as possible," said Ilya Yuffa, executive vice president and president of Lilly USA and Global Customer Capabilities. "Millions of Americans can now connect with a health care professional to determine if Foundayo is right for them and receive the medicine at their door through LillyDirect's free home delivery, or access it through telehealth providers or local retail pharmacies."

Foundayo is available starting at $149 per month at the lowest dose for self-pay patients.¹ Eligible and commercially insured people with coverage for Foundayo may pay as little as $25 per month with the Foundayo savings card.² Additionally, eligible Medicare Part D individuals may be able to get Foundayo for $50 per month, beginning July 1, 2026. To understand your options, visit www.foundayo.lilly.com.

Supported by the rigorous ATTAIN clinical trial program, Foundayo was proven to help people lose weight and keep it off. In the ATTAIN-1 trial, individuals taking the highest dose of Foundayo and who stayed on treatment lost an average of 27.3 pounds (12.4%) compared to 2.2 pounds (0.9%) with placebo.³ Participants taking Foundayo, regardless of trial completion, lost an average of 25 pounds (11.1%), compared to 5.3 pounds (2.1%) with placebo.⁴ In the ATTAIN program, Foundayo also led to reductions in many markers of cardiovascular risk, including waist circumference, non-HDL cholesterol, triglycerides and systolic blood pressure across all doses.

Use of Foundayo with other GLP-1 receptor agonist medicines is not recommended. It is not known whether Foundayo is safe and effective for use in children. Foundayo may cause tumors in the thyroid, including thyroid cancer. Watch for possible symptoms, such as a lump or swelling in the neck, hoarseness, trouble swallowing or shortness of breath. If you have any of these symptoms, tell your health care provider. The most common side effects of Foundayo include nausea, constipation, diarrhea, vomiting, indigestion, stomach (abdominal) pain, headache, swollen belly, feeling tired, belching, heartburn, gas, and hair loss. These are not all the possible side effects of Foundayo. Please see Indication and Safety Summary with Warning below and full Prescribing Information and Medication Guide.

To learn more about Foundayo, please visit www.foundayo.lilly.com. To learn more about LillyDirect, please visit www.lilly.com/lillydirect.

Obesity Medicine Access
Obesity remains one of the few major chronic diseases without consistent insurance coverage across U.S. health plans. Even as new medicines transform treatment, approximately half of Americans with employer-sponsored insurance lack coverage for obesity management medications.⁵ As part of Lilly's commitment to expanding obesity medicine access and improving affordability, Lilly has expanded self-pay access for individual patients.

About Foundayo (orforglipron)⁶
Foundayo™ (orforglipron) is FDA-approved for adults with obesity, or some adults with overweight who also have weight-related medical problems to reduce excess body weight and maintain weight reduction long term, alongside a reduced-calorie diet and increased physical activity. Foundayo is a once-daily small molecule (non-peptide) oral glucagon-like peptide-1 receptor agonist that can be taken any time of the day without restrictions on food and water intake.⁷ Orforglipron was discovered by Chugai Pharmaceutical Co., Ltd. and licensed by Lilly in 2018. Orforglipron is being studied in clinical trials for other conditions such as type 2 diabetes, obstructive sleep apnea, osteoarthritis knee pain, hypertension, peripheral artery disease and stress urinary incontinence.

About ATTAIN-1 and ATTAIN-2 clinical trial program
The ATTAIN Phase 3 global clinical development program for orforglipron has enrolled more than 4,500 people with obesity or overweight across two global registration trials.

ATTAIN-1 (NCT05869903) was a Phase 3, 72-week, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of orforglipron at various doses to placebo in adults with obesity, or overweight with at least one of the following comorbidities: hypertension, dyslipidemia, obstructive sleep apnea or cardiovascular disease, who did not have diabetes. The trial randomized 3,127 participants across the U.S., Brazil, China, India, Japan, South Korea, Puerto Rico, Slovakia, Spain and Taiwan to receive various doses of orforglipron or placebo along with healthy diet and physical activity. The primary objective of the study was to demonstrate that orforglipron is superior to placebo in body weight reduction from baseline after 72 weeks.

ATTAIN-2 (NCT05872620) was a Phase 3, 72-week, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of various doses of orforglipron with placebo in adults with obesity or overweight and type 2 diabetes. The trial randomized over 1,600 participants across the U.S., Argentina, Australia, Brazil, China, Czechia, Germany, Greece, India, South Korea and Puerto Rico to receive various doses of orforglipron or placebo along with healthy diet and physical activity. The primary objective of the study was to demonstrate that orforglipron is superior to placebo in mean body weight change from baseline at 72 weeks.

INDICATION AND SAFETY SUMMARY WITH WARNINGS
Foundayo™ (fown-DAY-oh) is a prescription medicine used with a reduced-calorie diet and increased physical activity to help adults with obesity, or some adults with overweight who also have weight-related medical problems, to lose excess body weight and keep the weight off.

• Foundayo should not be used with other GLP-1 receptor agonist medicines.
• It is not known if Foundayo is safe and effective for use in children.

Warnings – Foundayo may cause tumors in the thyroid, including thyroid cancer. Watch for possible symptoms, such as a lump or swelling in the neck, hoarseness, trouble swallowing, or shortness of breath. If you have any of these symptoms, tell your healthcare provider.

• Do not use Foundayo if you or any of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC).
• Do not use Foundayo if you have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
• Do not use Foundayo if you have had a serious allergic reaction to orforglipron or any of the ingredients in Foundayo.

Foundayo may cause serious side effects, including:

Inflammation of the pancreas (pancreatitis). Stop taking Foundayo and call your healthcare provider right away if you have severe pain in your stomach area (abdomen) that will not go away, with or without nausea or vomiting. Sometimes you may feel the pain from your abdomen to your back.

Severe stomach problems. Stomach problems, sometimes severe, have been reported in people who use Foundayo. Tell your healthcare provider if you have stomach problems that are severe or will not go away.

Dehydration leading to kidney problems. Diarrhea, nausea, and vomiting may cause a loss of fluids (dehydration), which may cause kidney problems. It is important for you to drink fluids to help reduce your chance of dehydration. Tell your healthcare provider right away if you have nausea, vomiting, or diarrhea that does not go away.

Low blood sugar (hypoglycemia). Your risk for getting low blood sugar may be higher if you use Foundayo with medicines that can cause low blood sugar, such as an insulin or sulfonylurea. Signs and symptoms of low blood sugar may include dizziness or light-headedness, sweating, confusion or drowsiness, headache, blurred vision, slurred speech, shakiness, fast heartbeat, anxiety, irritability, mood changes, hunger, weakness, or feeling jittery.

Serious allergic reactions. Stop using Foundayo and get medical help right away if you have any symptoms of a serious allergic reaction, including swelling of your face, lips, tongue or throat, problems breathing or swallowing, severe rash or itching, fainting or feeling dizzy, or very rapid heartbeat.

Changes in vision in patients with type 2 diabetes. Tell your healthcare provider if you have changes in vision during treatment with Foundayo.

Gallbladder problems. Gallbladder problems have happened in some people who use Foundayo. Tell your healthcare provider right away if you get symptoms of gallbladder problems, which may include pain in your upper stomach (abdomen), fever, yellowing of skin or eyes (jaundice), or clay-colored stools.

Food or liquid getting into the lungs during surgery or other procedures that use anesthesia or deep sleepiness (deep sedation). Foundayo may increase the chance of food getting into your lungs during surgery or other procedures. Tell your healthcare providers that you are taking Foundayo before you are scheduled to have surgery or other procedures.

Common side effects
The most common side effects of Foundayo include nausea, constipation, diarrhea, vomiting, indigestion, stomach (abdominal) pain, headache, swollen belly, feeling tired, belching, heartburn, gas, and hair loss. These are not all the possible side effects of Foundayo. Talk to your healthcare provider about any side effect that bothers you or doesn't go away.

Tell your doctor if you have any side effects. You can report side effects at 1-800-FDA-1088 or www.fda.gov/medwatch.

Before taking Foundayo

• Tell your healthcare provider about all the medicines you take. Foundayo may affect the way some medicines work, and some medicines may affect the way Foundayo works.
• Pregnancy Exposure Registry: There will be a pregnancy exposure registry for women who have taken Foundayo during pregnancy. The purpose of this registry is to collect information about the health of you and your baby. Talk to your healthcare provider about how you can take part in this registry, or you may contact Eli Lilly and Company at 1-800-LillyRx (1-800-545-5979).
• If you take birth control pills by mouth, talk to your healthcare provider before you take Foundayo. Birth control pills may not work as well while taking Foundayo. Your healthcare provider may recommend another type of birth control for 30 days after starting Foundayo and for 30 days after each dose increase of Foundayo.
• Talk to your healthcare provider about low blood sugar and how to manage it. Tell your healthcare provider if you are taking medicines to treat diabetes including an insulin or sulfonylurea.

Review these questions with your healthcare provider:

❑ Do you have other medical conditions, including problems with your pancreas or kidneys, or severe problems with your liver, severe problems with your stomach, such as slowed emptying of your stomach (gastroparesis) or problems digesting food?
❑ Do you have a history of diabetic retinopathy?
❑ Are you scheduled to have surgery or other procedures that use anesthesia or deep sleepiness (deep sedation)?
❑ Are you pregnant or plan to become pregnant? Foundayo may harm your unborn baby.
❑ Are you breastfeeding or plan to breastfeed? Breastfeeding is not recommended during treatment with Foundayo.
❑ Do you take any other prescriptions or over-the-counter medicines, vitamins, or herbal supplements?

How to take

• Take Foundayo exactly as your healthcare provider tells you to.
• Use Foundayo with a reduced-calorie diet and increased physical activity.
• Take Foundayo by mouth 1 time each day, with or without food.
• Swallow tablets whole. Do not break, crush, or chew the tablet.
• If you miss a dose, take it as soon as possible. Do not take 2 doses of Foundayo in the same day.
• Do not take more than 1 tablet per day.
• If you miss taking Foundayo for 7 or more days in a row, call your healthcare provider to talk about how to restart your treatment.
• If you take too much Foundayo, call your healthcare provider or Poison Help line at 1-800-222-1222 or go to the nearest hospital emergency room right away.

Learn more
Foundayo is a prescription medicine available in 0.8 mg, 2.5 mg, 5.5 mg, 9 mg, 14.5 mg, or 17.2 mg oral tablets. For more information, call 1-800-545-5979 or go to foundayo.lilly.com.

This summary provides basic information about Foundayo but does not include all information known about this medicine. Read the information that comes with your prescription each time your prescription is filled. This information does not take the place of talking with your doctor. Be sure to talk to your doctor or other healthcare provider about Foundayo and how to take it. Your doctor is the best person to help you decide if Foundayo is right for you.

OG CON BS APR2026

Foundayo^™ is a trademark of Eli Lilly and Company.

Endnotes and References 

1. For self-pay only. Prescription required. Terms apply. Additional taxes and fees may apply. One month is defined as 30 days. For full terms and conditions, learn more at foundayo.lilly.com.
2. Governmental beneficiaries excluded, terms and conditions apply. Learn more at foundayo.lilly.com.
3. The efficacy estimand represents efficacy had all randomized participants remained on study intervention (with possible dose interruptions and modifications) for 72 weeks without initiating prohibited weight management treatments.⁶
4. The treatment-regimen estimand represents the estimated average treatment effect regardless of adherence to study intervention or initiation of prohibited weight management treatments.⁶
5. International Foundation of Employee Benefit Plans. Pulse Survey: GLP-1 Drugs Corporate Only. Published 2024. Accessed November 5, 2025. https://www.ifebp.org/docs/default-source/pdf/resources---news/pulse-surveys/survey-glp-drugs-2024.pdf.
6. Foundayo. Prescribing Information. Lilly USA, LLC.
7. Ma X, Liu R, Pratt EJ, Benson CT, Bhattachar SN, Sloop KW. Effect of Food Consumption on the Pharmacokinetics, Safety, and Tolerability of Once-Daily Orally Administered Orforglipron (LY3502970), a Non-peptide GLP-1 Receptor Agonist. Diabetes Ther. 2024 Apr;15(4):819-832. https://doi.org/10.1007/s13300-024-01554-1. Epub 2024 Feb 24. PMID: 38402332; PMCID: PMC10951152.

About Lilly
Lilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit Lilly.com and Lilly.com/news, or follow us on Facebook, Instagram and LinkedIn. P-LLY

Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about Foundayo (orforglipron) as a treatment for adults with obesity or some adults with overweight who also have weight-related medical problems and reflects Lilly's current beliefs and expectations. However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of drug research, development, and commercialization. Among other things, there can be no guarantee that planned or ongoing studies will be completed as planned, that future study results will be consistent with the results to date, that orforglipron will receive additional regulatory approvals, or that orforglipron will be commercially successful or that we will meet anticipated timelines for its commercialization. For further discussion of these and other risks and uncertainties, see Lilly's most recent Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release.

Trademarks and Trade Names
All trademarks or trade names referred to in this press release are the property of the company, or, to the extent trademarks or trade names belonging to other companies are referenced in this press release, the property of their respective owners. Solely for convenience, the trademarks and trade names in this press release are referred to without the ^® and ™ symbols, but such references should not be construed as any indicator that the company or, to the extent applicable, their respective owners will not assert, to the fullest extent under applicable law, the company's or their rights thereto. We do not intend the use or display of other companies' trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies.

CMAT-20652 04/2026 ©Lilly USA, LLC 2026. All rights reserved.

Refer to:	Kristiane Silva Bello; bello_kristiane@lilly.com; 317-315-9052 (Media)
	Michael Czapar; czapar_michael_c@lilly.com; 317-617-0983 (Investors)

 

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/foundayo-orforglipron-lillys-new-oral-glp-1-pill-for-weight-loss-now-available-in-the-us-302737538.html

SOURCE Eli Lilly and Company

FAQ

When did Eli Lilly's Foundayo (LLY) become available in U.S. pharmacies?

Foundayo became available to U.S. retail pharmacies on April 9, 2026. According to the company, the drug was FDA approved on April 1, 2026 and is also accessible via LillyDirect and telehealth providers.

How much weight did patients lose in the ATTAIN-1 trial for Foundayo (LLY)?

At the highest dose, patients lost an average of 27.3 pounds (12.4%). According to the company, individuals who stayed on treatment averaged this reduction versus 2.2 pounds with placebo.

What will Foundayo (LLY) cost patients with and without insurance?

Self-pay patients face a starting cost of $149/month, while commercially insured patients may pay $25/month with the savings card. According to the company, eligible Medicare Part D individuals may pay $50/month starting July 1, 2026.

Can Foundayo (LLY) be taken with other GLP-1 medicines?

Use of Foundayo with other GLP-1 receptor agonists is not recommended. According to the company, safety and effectiveness in combination with other GLP-1 medicines have not been established.

What are the main safety warnings and common side effects for Foundayo (LLY)?

Foundayo may cause thyroid tumors, including thyroid cancer, and patients should monitor related symptoms. According to the company, common side effects include nausea, constipation, diarrhea, vomiting, abdominal pain, headache, and fatigue.